Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Recurrent or metastatic nasopharyngeal carcinoma

Patient must have a WHO performance status of no higher than 2; AND

The condition must not be amenable to salvage surgery or radiotherapy; AND

Patient must not have received prior treatment with a programmed cell death-1 (PD-1) inhibitor or a programmed cell death ligand-1 (PD-L1) inhibitor for this condition; AND

The treatment must be commenced in combination with platinum-based chemotherapy (PBC) where the patient has not previously received systemic therapy for this condition in the metastatic setting (i.e. used in combination with PBC for 6 cycles in the first line setting unless intolerance/contraindication is confirmed); or

The treatment must be the sole PBS-subsidised therapy at the time of treatment initiation where the condition has progressed following treatment with PBC (i.e. used as monotherapy in the second line setting); AND

Patient must not be undergoing treatment with this drug as a PBS benefit where the treatment duration extends beyond the following, whichever comes first: (i) disease progression despite treatment with this drug, (ii) 24 cumulative months from treatment initiation; annotate any remaining repeat prescriptions with the word 'cancelled' where this occurs.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 2

An increase above the listed maximum amount may only be requested when a dose of 3 mg/kg every 2 weeks is prescribed in the second line setting.